SCHEMBL718165

SCHEMBL718165

CCc1n[nH]cc1C(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.40
MAP2K1 Q02750 1/20 0.38
NR4A2 P43354 2/20 0.38
CREBBP Q92793 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPK1 P28482 1/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
GABRA4 P48169 1/20 0.37
GABRE P78334 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716791 0.86 TSHR (0.38) TSHRMAP2K1NR4A2CREBBPKMT2A
SCHEMBL3356162 0.84 KMT2A (0.49) TSHRKMT2AMAPK1GABRA1GABRB2
SCHEMBL369544 0.84 NPC1 (0.39) TSHRMAP2K1NR4A2CREBBPNPC1
SCHEMBL27645956 0.83 RIPK1 (0.39) TSHRMAP2K1NR4A2CREBBPKMT2A
SCHEMBL16974055 0.82 HCAR2 (0.41) TSHRMAP2K1NR4A2CREBBPKMT2A
SCHEMBL15309515 0.81 CYP3A4 (0.36) TSHRNPC1KMT2AGABRPGABRD
SCHEMBL553835 0.81 GABRP (0.44) TSHRNPC1RAB9AKMT2AGABRP
SCHEMBL8092224 0.80 CNR2 (0.39) TSHRKMT2ALMNAALDH1A1
SCHEMBL31624309 0.80 TSHR (0.36) TSHRMAP2K1NR4A2CREBBPKMT2A
SCHEMBL27860338 0.79 HMGCR (0.37) KMT2AGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102015641-B Heterocyclic compound TAKEDA PHARMACEUTICAL 2014-01-01 CN disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
CN-102015641-A Heterocyclic compound TAKEDA PHARMACEUTICAL 2011-04-13 CN disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP TSHR 1555/4885MAP2K1 2166/4885NR4A2 696/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP TSHR 1555/4885MAP2K1 2166/4885NR4A2 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.